<DOC>
	<DOCNO>NCT00289185</DOCNO>
	<brief_summary>GSK Biologicals partnership Malaria Vaccine Initiative PATH develop candidate malaria vaccine GSK 257049 routine immunization infant child live malaria endemic area . The vaccine would offer protection malaria disease due parasite Plasmodium falciparum . The vaccine would also provide protection infection hepatitis B virus ( HBV ) . In order integrate malaria vaccine EPI regimen malaria-endemic region , new variant RTS , S/AS02D ( 0.5 mL dose ) develop . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Study Safety , Immunogenicity Efficacy Candidate Malaria Vaccine Tanzanian Infants</brief_title>
	<detailed_description>This phase 2b trial design evaluate safety immunogenicity RTS , S/AS02D co-administered multivalent DTPw/Hib ( Aventis Pasteur 's TETRActHib vaccine ) . Infants randomize control group receive license hepatitis B vaccine , Engerix-B place RTS , S/AS02D . Data pertaining RTS , S/AS02D Engerix-B collect double blinded manner ; data relate TETRActHib collect open fashion . Oral polio vaccine ( OPV ) administer birth , 8 , 12 , 16 week co-administration vaccine administer part protocol . Antibody titer OPV assess part protocol .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male female infant 6 10 week age time first vaccination . Written oral , sign thumbprinted witness informed consent obtain parent ( ) /guardian ( ) child . Subjects investigator believe parents/guardians comply requirement protocol ( e.g . return followup visit ) . Born mother HBsAg negative &amp; HIV negative . Born normal gestation period ( 36 42 week ) . Subjects live within 5 km radius dispensary . Exclusion criterion : Acute disease time enrolment . Serious acute chronic illness determine clinical physical examination laboratory screen test . Laboratory screen test range haemoglobin , total white cell count , platelet , ALT creatinine . Previous vaccination diphtheria , tetanus , pertussis ( wholecell acellular ) , Hemophilus influenzae type b hepatitis B vaccine . BCG administration within one week propose administration study vaccine . Planned administration/administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) . Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins , blood transfusion blood product within three month precede first dose study vaccine plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Previous participation malaria vaccine trial . Simultaneous participation clinical trial . Same sex twin . Maternal death . History allergic reaction ( significant IgEmediated event ) anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component vaccine . Any finding investigator feel would increase risk adverse outcome participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Coccidiosis</keyword>
	<keyword>Parasitic Diseases</keyword>
	<keyword>Malaria , Falciparum</keyword>
	<keyword>Malaria</keyword>
</DOC>